Background/Aims Despite the disproportionally high prevalence rates of hepatitis C virus (HCV) amongst the incarcerated population, eradication remains challenging due to logistic and financial barriers. Although treatment prioritization based on disease severity is commonly practiced, the efficacy of such approach remained uncertain. We aimed to compare the impact of unrestricted access to direct-acting antiviral (DAA) among incarcerated HCV-infected patients in Singapore.
Methods In this retrospective study, we reviewed all incarcerated HCV-infected patients treated in our hospital during the restricted DAA era (2013–2018) and unrestricted DAA access era (2019). Study outcomes included the rate of sustained virological response (SVR), treatment completion and treatment default. Subgroup analysis was performed based on the presence of liver cirrhosis, HCV genotype and HCV treatment types.
Results A total of 1,001 HCV patients was followed-up for 1,489 person-year. They were predominantly male (93%) with genotype-3 HCV infection (71%), and 38% were cirrhotic. The overall SVR during the restricted DAA access era and unrestricted DAA access era were 92.1% and 99.1%, respectively. Unrestricted access to DAA exponentially improved the treatment access among HCV-infected patients by 460%, resulting in a higher SVR rate (99% vs. 92%, P=0.003), higher treatment completion rate (99% vs. 93%, P<0.001) and lower treatment default rate (1% vs. 9%, P<0.001).
Conclusion In this large cohort of incarcerated HCV-infected patients, we demonstrated that unrestricted access to DAA is an impactful strategy to allow rapid treatment up-scale in HCV micro-elimination.
Citations
Citations to this article as recorded by
Editorial on “Direct-acting antiviral therapy for patients with HCV-related hepatocellular carcinoma: A nationwide cohort study” Yan Ling Ong, Apichat Kaewdech, Daniel Q Huang, Yu Jun Wong Clinical and Molecular Hepatology.2026; 32(1): 407. CrossRef
Hepatitis C elimination in Singapore: Current status and future directions JWE Quek, D Varun, JH Loo, KC Yew, J Hsiang, PH Thurairajah, C‐K Tan, R Kumar, YJ Wong Journal of Gastroenterology and Hepatology.2025; 40(1): 339. CrossRef
Status of hepatitis B virus and hepatitis C elimination in Singapore: a call for action Yu Jun Wong, Daniel Huang Singapore Medical Journal.2025; 66(7): 376. CrossRef
Elimination of chronic viral hepatitis C in correctional health Rahul Kumar, Yu Jun Wong, Jessica Tan Singapore Medical Journal.2025; 66(Suppl 1): S70. CrossRef
Global epidemiology, natural history, maternal-to-child transmission, and treatment with DAA of pregnant women with HCV: a systematic review and meta-analysis Joo Wei Ethan Quek, Jing Hong Loo, En Qi Lim, Ambrose Hon-Lam Chung, Abu Bakar Bin Othman, Jarell Jie-Rae Tan, Scott Barnett, Mindie H. Nguyen, Yu Jun Wong eClinicalMedicine.2024; 74: 102727. CrossRef
Liver diseases and hepatocellular carcinoma in the Asia-Pacific region: burden, trends, challenges and future directions Lung-Yi Mak, Ken Liu, Sakkarin Chirapongsathorn, Kuo Chao Yew, Nobuharu Tamaki, Ruveena Bhavani Rajaram, Mara Teresa Panlilio, Rashid Lui, Hye Won Lee, Jimmy Che-To Lai, Anand V. Kulkarni, Madhumita Premkumar, Cosmas Rinaldi Adithya Lesmana, Yao Chun Hsu, Nature Reviews Gastroenterology & Hepatology.2024; 21(12): 834. CrossRef
Baveno-VII criteria to predict decompensation and initiate non-selective beta-blocker in compensated advanced chronic liver disease patients Yu Jun Wong, Chen Zhaojin, Guilia Tosetti, Elisabetta Degasperi, Sanchit Sharma, Samagra Agarwal, Liu Chuan, Chan Yiong Huak, Li Jia, Qi Xiaolong, Anoop Saraya, Massimo Primignani Clinical and Molecular Hepatology.2023; 29(1): 135. CrossRef
Response to antiviral therapy for chronic hepatitis C and risk of hepatocellular carcinoma occurrence in Japan: a systematic review and meta-analysis of observational studies Yoko Yamagiwa, Keitaro Tanaka, Keitaro Matsuo, Keiko Wada, Yingsong Lin, Yumi Sugawara, Tetsuya Mizoue, Norie Sawada, Hidemi Takimoto, Hidemi Ito, Tetsuhisa Kitamura, Ritsu Sakata, Takashi Kimura, Shiori Tanaka, Manami Inoue, Sarah Krull Abe, Shuhei Nomur Scientific Reports.2023;[Epub] CrossRef
Access to Hepatitis C Treatment during and after Incarceration in New Jersey, United States: A Qualitative Study Samir Kamat, Sankeerth Kondapalli, Shumayl Syed, Gabrielle Price, George Danias, Ksenia Gorbenko, Joel Cantor, Pamela Valera, Aakash K. Shah, Matthew J. Akiyama Life.2023; 13(4): 1033. CrossRef
Minimal monitoring is a safe but underutilised strategy for hepatitis C virus treatment in Singapore Wei Xuan Tay, Samantha Jingyun Koh, Francis Kok Ban Teh, Yu Bin Tan, Tian Yu Qiu, Linn War Mai, Vivien Li Xin Wong, Jessica Tan, Andrew Kwek, Kwong Ming Fock, Tiing Leong Ang, Rahul Kumar, Yu Jun Wong Annals of the Academy of Medicine, Singapore.2023; 52(6): 321. CrossRef
HCV Microelimination for High-risk Special Populations Chung-Feng Huang, Guan-Jhou Chen, Chien-Ching Hung, Ming-Lung Yu The Journal of Infectious Diseases.2023; 228(Supplement): S168. CrossRef
Efficacy and safety of sofosbuvir/velpatasvir with or without ribavirin in hepatitis C genotype 3 compensated cirrhosis: A meta-analysis Jing Hong Loo, Wen Xin Flora Xu, Jun Teck Low, Wei Xuan Tay, Le Shaun Ang, Yew Chong Tam, Prem Harichander Thurairajah, Rahul Kumar, Yu Jun Wong World Journal of Hepatology.2022; 14(6): 1248. CrossRef
HCV Infection and Liver Cirrhosis Are Associated with a Less-Favorable Serum Cholesteryl Ester Profile Which Improves through the Successful Treatment of HCV Kilian Weigand, Georg Peschel, Jonathan Grimm, Martina Müller, Marcus Höring, Sabrina Krautbauer, Gerhard Liebisch, Christa Buechler Biomedicines.2022; 10(12): 3152. CrossRef
Brief Report: HCV Universal Test-and-Treat With Direct Acting Antivirals for Prisoners With or Without HIV: A Prison Health Care Workers–Led Model for HCV Microelimination in Thailand Ruamthip Supanan, Win Min Han, Weerakit Harnpariphan, Thornthun Ueaphongsukkit, Sasiwimol Ubolyam, Jiratchaya Sophonphan, Pisit Tangkijvanich, Sombat Thanprasertsuk, Anchalee Avihingsanon JAIDS Journal of Acquired Immune Deficiency Syndromes.2021; 88(5): 465. CrossRef
First
Prev
